Status: Recruiting
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat will be given in combination with gilteritinib, a drug that is already approved to treat patients with FLT3-mutated R/R AML.
Participants needed: 50
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Oryzon Genomics S.A.Updated: Jul 29, 2024Locations: 13
Eligibility criteria
Diagnosis of primary AML or AML with myelodysplasia-related changes (AML-MRC) [+8]
Diagnosis of acute promyelocytic leukemia. [+12]